Literature DB >> 12022380

Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?

Maurie Markman1.   

Abstract

Cancer patients and their families often ask their primary care physicians if a new treatment reported in the news can help them. Physicians familiar with the long and complicated process of oncologic clinical trials are in the best position to assess the potential for clinical benefit from a new antineoplastic therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12022380     DOI: 10.3949/ccjm.69.5.368

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  1 in total

1.  Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Authors:  Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.